Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | PRKCI |
| Gene Name: | PRKCI |
| Protein Full Name: | Protein kinase C iota type |
| Alias: | APKC-lambda,iota; EC 2.7.11.13; HINT1; KPCI; NPKC-iota; PKC lambda; PKC-iota; PKCL |
| Mass (Da): | 68262 |
| Number AA: | 596 |
| UniProt ID: | P41743 |
| Locus ID: | 5584 |
| COSMIC ID: | PRKCI |
| Gene location on chromosome: | 3q26.2 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20448 |
| Percent of cancer specimens with mutations: | 0.64 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | PRKCI is a calcium- and DAG-dependent protein serine/threonine kinase that protects against apoptosis and is involved in NF-kB activation, cell survival and differentiation. It is also known to be required for BCR-ABL oncogene-mediated resistance to apoptotic drugs in leukemia cells. It can prevent apoptosis by phosphorylating and inhibiting the pro-apoptotic factor BAD. PRKCI can interact and form a complex with PARD6A and ECT2 and promote transformed growth and invasion. A P118L mutation has been associated with a metastatic melanoma sample. |